Optiscan (ASX:OIL) has advised that its partner MR Solutions has introduced it CellLIVE pre-clinical research imaging system based on Optiscan’s second generation endomicroscopy platform to the market.
The introduction of the system includes an inaugural demonstration at the World Molecular Imaging Conference (WMIC) in Seoul, Korea this month.
Sales are expected to begin within six months subject to completion of key tasks and required regulatory clearances.
As MR Solutions’ CellLIVE is a research platform and not a medical device, no clinical trials or medical device approval submissions are required and the process is regarded by the company as low risk.
Optiscan’s second generation platform offers features not available in the first generation including full 3D imaging capabilities and seamless integration of advance analysis software.
Its technology allows microscopic imaging of up to 1000 times magnification to be achieved, allowing doctors to instantly see cellular level details of tissue without the requirement to surgically remove tissue, known as a biopsy.
The company had earlier this month concluded a placement priced at $0.03 per share and convertible note issue that will raise a total of $750,000.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.